Current status of targeted therapy for cholangiocarcinoma
10.3760/cma.j.cn115396-20230520-00134
- VernacularTitle:胆管癌靶向治疗的现状
- Author:
Huicong HUANG
1
;
Jian DUAN
;
Zhe QING
;
Jinlan HE
Author Information
1. 昆明医科大学研究生院，昆明 650032
- Keywords:
Bile duct neoplasms;
Gene fusion;
Mutation;
Target molecular;
Targeted therapy
- From:
International Journal of Surgery
2023;50(8):567-571
- CountryChina
- Language:Chinese
-
Abstract:
Cholangiocarcinoma is a group of highly invasive and heterogeneous biliary malignancies originating from any part of the biliary tree. At present, the most ideal treatment is still radical surgery.Gemcitabine combined with cisplatin (gem-cis) has been recognized as the standard first-line chemotherapy regimen for patients with unresectable, advanced or metastatic disease.In recent years, with the proposal of precision medicine and the development of next-generation sequencing technologies, A large number of important cholangiocarcinoma targets have been discovered, such as FGFR, IDH, VEGFR, BRAF, MET, etc., and the research on corresponding target drugs is booming.By referring to relevant literature and data, combined with domestic and foreign clinical trials, this paper reviews the important targets of cholangiocarcinoma and the latest progress of targeted drug therapy.
